Cargando…

HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV

BACKGROUND: In order to develop a more effective prophylactic HIV-1 vaccine it is important optimize the components, improve Envelope glycoprotein immunogenicity as well as to explore prime-boost immunization schedules. It is also valuable to include several HIV-1 subtype antigens representing the w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hinkula, J, Petkov, S, Ljungberg, K, Hallengärd, D, Bråve, A, Isaguliants, M, Falkeborn, T, Sharma, S, Liakina, V, Robb, M, Eller, M, Moss, B, Biberfeld, G, Sandström, E, Nilsson, C, Markland, K, Blomberg, P, Wahren, B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496381/ https://www.ncbi.nlm.nih.gov/pubmed/28721397 http://dx.doi.org/10.1016/j.heliyon.2017.e00339

Ejemplares similares

Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost
por: Joachim, Agricola, et al.
Publicado: (2020)

A combination of intradermal jet-injection and electroporation overcomes in vivo dose restriction of DNA vaccines
por: Hallengärd, David, et al.
Publicado: (2012)

Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate
por: Currier, Jeffrey R., et al.
Publicado: (2010)

P19-29. Determining the optimal protocol for plasmid DNA vaccine delivery by intradermal in vivo electroporation
por: Hallengärd, D, et al.
Publicado: (2009)

Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses
por: Stenler, S., et al.
Publicado: (2017)

Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation
por: Bråve, Andreas, et al.
Publicado: (2010)

OA04-02. Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara (MVA) heterologous boost vaccinees
por: Nilsson, C, et al.
Publicado: (2009)

HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial
por: Nilsson, Charlotta, et al.
Publicado: (2015)

Potent cellular and humoral immunity against HIV-1 elicited in mice by a DNA-prime/MVA-boost vaccine regimen intended for human use
por: Wahren, Britta, et al.
Publicado: (2006)

Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime
por: Bauer, A, et al.
Publicado: (2012)

Endocine™, N3OA and N3OASq; Three Mucosal Adjuvants That Enhance the Immune Response to Nasal Influenza Vaccination
por: Falkeborn, Tina, et al.
Publicado: (2013)

Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults
por: Joachim, A, et al.
Publicado: (2012)

DNA Vaccine Development at Pre- and Post-Operation Warp Speed
por: Ljungberg, Karl, et al.
Publicado: (2020)

Immunotherapy with an HIV-DNA Vaccine in Children and Adults
por: Palma, Paolo, et al.
Publicado: (2014)

Enrolment and logistical challenges in TaMoVac 01 Phase I/II HIV trial despite the completion of an earlier (HIVIS-03 trial trial) in Dar es Salaam
por: Ngatoluwa, M, et al.
Publicado: (2012)

DNA-Encoded Flagellin Activates Toll-Like Receptor 5 (TLR5), Nod-like Receptor Family CARD Domain-Containing Protein 4 (NRLC4), and Acts as an Epidermal, Systemic, and Mucosal-Adjuvant
por: Nyström, Sanna, et al.
Publicado: (2013)

Receptor Binding by Cholera Toxin B-Subunit and Amino Acid Modification Improves Minimal Peptide Immunogenicity
por: Boberg, Andreas, et al.
Publicado: (2012)

Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania - the phase I/II HIVIS 03 trial
por: Bakari, Muhammad, et al.
Publicado: (2013)

P14-14 LB. A low dose of multigene, multiclade HIV DNA given intradermally induces strong and broad immune responses after boosting with heterologous HIV MVA
por: Bakari, M, et al.
Publicado: (2009)

Immunization with HIV protease peptides linked to syngeneic erythrocytes
por: Boberg, Andreas, et al.
Publicado: (2007)

A Novel Class of Anti-HIV Agents with Multiple Copies of Enfuvirtide Enhances Inhibition of Viral Replication and Cellular Transmission In Vitro
por: Chang, Chien-Hsing, et al.
Publicado: (2012)

Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers
por: Joachim, Agricola, et al.
Publicado: (2020)

Long-Lasting Mucosal and Systemic Immunity against Influenza A Virus Is Significantly Prolonged and Protective by Nasal Whole Influenza Immunization with Mucosal Adjuvant N3 and DNA-Plasmid Expressing Flagellin in Aging In- and Outbred Mice
por: Hinkula, Jorma, et al.
Publicado: (2019)

CN54gp140: product characteristics, peclinical and clinical use - recombinant glycoprotein for HIV immunization
por: Katinger, D, et al.
Publicado: (2012)

Potent Functional Antibody Responses Elicited by HIV-I DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults
por: Joachim, Agricola, et al.
Publicado: (2015)

Do circulating HIV vaccine plasmids contribute to immunogenicity in humans?
por: Wahren, B, et al.
Publicado: (2006)

The intranasal adjuvant Endocine™ enhances both systemic and mucosal immune responses in aged mice immunized with influenza antigen
por: Falkeborn, Tina, et al.
Publicado: (2017)

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen
por: Podola, L, et al.
Publicado: (2012)

Skin Electroporation: Effects on Transgene Expression, DNA Persistence and Local Tissue Environment
por: Roos, Anna-Karin, et al.
Publicado: (2009)

DNA immunization site determines the level of gene expression and the magnitude, but not the type of the induced immune response
por: Petkov, Stefan, et al.
Publicado: (2018)

Binding of undamaged double stranded DNA to vaccinia virus uracil-DNA Glycosylase
por: Schormann, Norbert, et al.
Publicado: (2015)

DNA-PK Is Targeted by Multiple Vaccinia Virus Proteins to Inhibit DNA Sensing
por: Scutts, Simon R., et al.
Publicado: (2018)

Oral delivery of transgenic plant-derived HIV-1 p24 antigen in low doses shows a superior priming effect in mice compared to higher doses
por: Lindh, I, et al.
Publicado: (2012)

Vaccinia Virus Activation and Antagonism of Cytosolic DNA Sensing
por: El-Jesr, Misbah, et al.
Publicado: (2020)

Alphavirus Replicon DNA Expressing HIV Antigens Is an Excellent Prime for Boosting with Recombinant Modified Vaccinia Ankara (MVA) or with HIV gp140 Protein Antigen
por: Knudsen, Maria L., et al.
Publicado: (2015)

Correction: DNA immunization site determines the level of gene expression and the magnitude, but not the type of the induced immune response
por: Petkov, Stefan, et al.
Publicado: (2021)

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine
por: Munseri, P, et al.
Publicado: (2012)

HIV-1 Protease as DNA Immunogen against Drug Resistance in HIV-1 Infection: DNA Immunization with Drug Resistant HIV-1 Protease Protects Mice from Challenge with Protease-Expressing Cells
por: Petkov, Stefan, et al.
Publicado: (2022)

Hepatitis C Virus Core Protein Transforms Murine Fibroblasts by Promoting Genomic Instability
por: Smirnova, Irina S., et al.
Publicado: (2006)

Structure of the uracil complex of Vaccinia virus uracil DNA glycosylase
por: Schormann, N., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_q69lge31qnvj76d724jubmsc1b